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Background: Exercise has been shown to be beneficial for patients with cystic fibrosis (CF), but for some CF patients there is a risk of
desaturation, although the predicting factors are not conclusive or reliable. We sought to determine the relationship between the diffusion
capacity of the lungs for nitric oxide and carbon monoxide (DLNO and DLCO) and the components of DLCO: alveolar-capillary
membrane conductance (DM), and pulmonary capillary blood volume (VC) on peripheral oxygen saturation (SaO2) at rest and during
exercise in CF.
Methods: 17 mild/moderate CF patients and 17 healthy subjects were recruited (age=26±7 vs. 23±8 years, ht=169±8 vs. 166±8 cm, wt=65±9
vs. 59±8 kg, BMI=23±3 vs. 22±3 kg/m2, VO2PEAK=101±36 vs. 55±25%pred., FEV1=92±22 vs. 68±25%pred., for healthy and CF,
respectively, mean±SD, VO2PEAK and FEV1 pb0.001). Subjects performed incremental cycle ergometry to exhaustion with continuous
monitoring of SaO2 and measures of DLNO, DLCO, DM and VC at each stage.
Results: CF patients had a lower SaO2 at rest and peak exercise (rest=98±1 vs. 96±1%, peak=97±2 vs. 93±5%, for healthy and CF,
respectively, pb0.01). At rest, DLNO, DLCO, DM were significantly lower in the CF group (pb0.01). The difference between groups was
augmented with exercise (DLNO=117±4 vs. 73±3 ml/min/mmHg; DLCO=34±8 vs. 23±8 ml/min/mmHg; DM=50±1 vs. 34±1, pb0.001, forAbbreviations: CI, cardiac index; CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane regulator; DLCO, diffusion capacity of the lungs for carbon monoxide;
DLNO, diffusion capacity of the lungs for nitric oxide; DM, alveolar-capillary membrane conductance; FEF25–75, forced expiratory flow at 25–75% of forced vital
capacity; FEF50, expiratory flow at 50% of forced vital capacity; FEV1, forced expiratory volume in one second of forced vital capacity; FVC, forced vital capacity;
HR, heart rate; MEFV, maximal expiratory flow volume; MTT, mean transit time; Q, cardiac output; RR, respiratory rate; SaO2, peripheral oxygen saturation; VA,
alveolar volume; VD, dead space volume; VC, pulmonary capillary blood volume; VE, minute ventilation VT, tidal volume; VO2, oxygen uptake; WMAX, workload as a
percentage of predicted.
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46 C.M. Wheatley et al. / Journal of Cystic Fibrosis 10 (2011) 45–53healthy and CF respectively). Peak SaO2 was related to resting DLNO in CF patients (r=0.65, p=0.003).
Conclusions: These results suggest a limitation in exercise-mediated increases in membrane conductance in CF which may contribute to a drop in
SaO2 and that resting DLNO can account for a large portion of the variability in SaO2.
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Subject demographics.
Healthy CF CI 95%
n 17 17
Gender (% female) 47 29 (−0.5, 0.2)
Age (years) 26±7 23±8 (−2.4, 8.1)
Height (cm) 169±8 166±8 (−2.3, 8.7)
Weight (kg) 65±9 59±9 (−0.7, 11.7)
BMI (kg/m2) 23±3 22±3 (−0.8, 3.3)
BSA (m2) 1.7±0.1 1.7±0.1 (−0.0, 0.2)
Hemoglobin (g/dl) 14.5±1.3 14.4±1.7 (−1.1, 1.2)
VO2PEAK (% predicted) 101±36 55±25 † (23.5, 67.7)
CF = cystic fibrosis; BSA = body surface area, VO2peak = maximal oxygen
consumption;
Values are mean±SD and CI 95% is for the mean difference. † pb0.001.1. Introduction
Exercise is increasingly prescribed in patients with cystic
fibrosis (CF) since it has been shown to improve quality of life,
increase exercise tolerance, increase respiratory muscle endur-
ance, reduce residual volume, increase mucus clearance and
reduce the rate of decline in pulmonary function [1–8].
Additionally, increased aerobic fitness (VO2MAX) has been
shown to extend life expectancy in patients with CF [9]. A
problem in prescribing exercise as therapy is that exercise
tolerance is often greatly reduced in patients with CF and many
studies have noted marked reduction in peripheral oxygen
saturation (SaO2) during exercise [10–19]. The mechanism of
this desaturation is not completely understood, but possible
explanations for the phenomenon include slower O2 kinetics,
ventilation–perfusion mismatch, pulmonary function impair-
ments, or insufficient gas diffusion [14,16,18,20,21]. Gas
diffusion can be assessed by the measurement of diffusion
capacity of the lungs for carbon monoxide (DLCO) which is
dependent on both alveolar-capillary membrane conductance
(DM) and pulmonary capillary volume (VC). Using simulta-
neous measurement of DLCO with the diffusion capacity of the
lungs for nitric oxide (DLNO), these components of DLCO can
be partitioned out [22–25]. Although the combined assessment
of DLCO and DLNO provides important information about gas
diffusion, DLNO independently provides a direct measure of
DM. When measuring DLNO, the influence of VC is considered
negligible due to the high reaction rate of NO with hemoglobin.
Consequently, the DLNO is limited primarily by the transfer of
gas across the membrane [23,26,27].
Recently, Dressel et al. have demonstrated that the
quantification of membrane diffusion using DLNO was better
correlated with CF-specific CT score than DLCO, concluding
that DLNO was a suitable measure to quantify destruction
and structural alterations in the CF lung [28]. DLNO and the
components of DLCO have not been reported during exercise
in CF, and there are inconsistent findings about a relationship
between DLCO and SaO2 [16,29–31]. Therefore, we sought
to assess the association between DLNO, DLCO, DM, and VC
with SaO2 in CF subjects during exercise when compared to
healthy subjects. Additionally, we sought to determine if the
measurement of DLCO/DLNO at rest could assist in
predicting exercise-induced desaturation in individuals with
CF. We hypothesized that DLNO, DLCO and DM at peak
exercise would demonstrate a positive relationship with peak
SaO2 and that DLNO at rest, as a measure of membrane
conductance, would be a strong predictor of desaturation in
CF individuals.2. Methods
2.1. Subjects
Seventeen mild to moderate CF subjects, confirmed by a
positive sweat test (≥60 mmol/l Cl−) and at least one ΔF508
deletion, along with seventeen control subjects matched for age,
gender, height and weight were recruited for this study (subject
demographics, Table 1). To ensure CF patients were clinically
stable for participation in the study, CF subjects were excluded
if they had a FEV1≤40% predicted, had experienced a
pulmonary exacerbation within the last two weeks or pulmonary
hemorrhage within six months resulting in greater than 50 cc of
blood in the sputum, were taking any antibiotics for pulmonary
exacerbation, or if they were taking any experimental drugs
related to CF. Cystic fibrosis patients were recruited through the
Arizona Respiratory Center at the University of Arizona
Medical Center and its affiliated CF clinic. Control subjects
were recruited through advertising posted around the University
of Arizona and by word of mouth. The protocol was reviewed
and approved by the University of Arizona Institutional Review
Board. All participants provided written informed consent prior
to study, and all aspects of the study were performed according
to the declaration of Helsinki.
2.2. Protocol
Upon arrival, subjects were outfitted with a 12-lead
electrocardiogram (Marquette Electronics, Milwaukee, WI) to
monitor heart rate (HR) and then completed pulmonary function
testing according to ATS standards. Predicted values for all
pulmonary function measures were based on predicted
equations from NHANES III [32]. Simultaneous measurements
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and during each stage of exercise to exhaustion. Peripheral
oxygen saturation was assessed by pulse oximetry with a finger
sensor (Nellcor N-600 Pulse Oximeter, Bolder, CO). Accurate
SaO2 values were ensured by instructing the subject to maintain
a relaxed grip and confirming there were no discrepancies in HR
between the pulse oximeter and the ECG. All progressive
exercise tests were performed on the same cycle ergometer
(Corival Lode B.V., The Netherlands). The testing protocol
used was subject-specific as it was based on the subject's body
size and on the type and intensity of the subject's typical
physical activity. The initial workload chosen also served as the
incremental workload increase at each stage of the exercise test.
Exhaustion of subjects was determined by an inability to
maintain a pedal rate between 60 and 80 rpm, a respiratory
exchange ratio greater than 1.15, or a rating of perceived
exertion of 18 or greater [33]. The test ended when two out of
the three were demonstrated, or at the subject's request.
Oxygen uptake (VO2), carbon dioxide production, respira-
tory rate (RR), tidal volume (VT), and minute ventilation (VE)
were continuously monitored and averaged every three seconds
at rest and during exercise. For flow and gas exchange analysis,
a Medical Graphics CPX/D (St. Paul, MN) metabolic cart was
interfaced with a Perkin Elmer MGA-1100 mass spectrometer
(Wesley, MA). Predicted VO2PEAK and maximum workload
(WMAX) were calculated according to equations by Hansen et
al. [34].
2.3. Measurement of cardiac output, alveolar-capillary
membrane conductance, and pulmonary capillary blood volume
Measurements of DLCO and DLNO were performed
simultaneously with the measurement for Q which allowed for
the assessment of DM and VC at rest and during each stage of
exercise as previously described [23,25,35,55]. Briefly, Q,DLCO
and DLNO were assessed using the rebreathe technique where
subjects breathed through a pneumotachograph connected to a
non-rebreathing Y-valve (Hans Rudolph, KC, MO) with the
inspiratory port connected to a pneumatic switching valve. This
valve allowed for rapid switching between breathing room air and
breathing from a 5-liter anesthesia rebreathe bag containing 0.7%
C2H2, 9% He, 0.3% carbon monoxide (C
18O), 40 PPM NO
(diluted immediately before the test in the bag from an 800 PPM
gas mixture), and 35%O2. It is important to note that only the first
inspired breath contains 40PPM NO. This has been shown to not
result in artificial alterations in DLCO or VC [23,36]. Gases were
sampled using the mass spectrometer and NO analyzer (Sievers
Instruments, Boulder, CO) which was integrated with custom
analysis software for the determination of DLCO, DLNO and Q
[25,37]. The NO analyzer was calibrated prior to each visit using
an NO filter and NO gas (45 ppm) for the zero and second
calibration points, respectively. At rest, the rebreathe bag was
filled with 1575 ml of gas. During exercise, the bag volume was
dictated by the subject's tidal volume with 500 ml extra added to
ensure the bag did not collapse at the end of inspiration, but that
there was not excess of gas within the bag during the maneuver.
At the end of a normal expiration, the subjects were switched intothe rebreathe bag and instructed to nearly empty the bagwith each
breath for 8–10 consecutive breaths. The subject's RR was
controlled at 32 breaths/min with a metronome at rest and during
exercise unless the subject's natural RR exceeded 32 breaths/min.
Accurate bag volumes were assured using a timed switching
circuit which, given a consistent flow rate from the tank, produced
the desired bag volume. The switching circuit and tank were
calibrated and tested prior to each test to ensure accurate volumes.
Following each maneuver, the rebreathe bag was emptied with a
suction device and refilled immediately prior to the next
maneuver. At the start of each maneuver, there was no residual
gas in the dead space of the apparatus, nor from the exhaled air
from the subjects, as determined through gas sampling with the
mass spectrometer.
The rate of disappearance of acetylene from the exhaled gas
mixture during rebreathing was used to assess cardiac output.
Since acetylene does not bind to hemoglobin, the rate of
disappearance of acetylene is limited primarily by the rate at
which a new volume of blood is transported through the lungs.
Because all the blood in the pulmonary circulation per minute is
equal to the volume of blood in the systemic circulation per
minute the measure of the disappearance of acetylene provides a
measure of cardiac output [35]. The rate of disappearance of
acetylene with each breath was calculated from the slope of the
exponential disappearance of acetylene with respect to the
helium using custom software [25].
According to the model of the diffusion capacity of the lungs
described by Roughton and Forster, DM and VC can be
determined [23,38]:
1
DLCO
=
1
DMCO
+
1
θCO⋅VC
To calculate the DMCO, DLNOwhich was considered equal to
DMNO was taken and adjusted for differences in the diffusion
constants of CO and NO based on molecular weight and
solubility using a correction factor of 2.11 which Ceridon et al.
demonstrated is most appropriate during exercise [39]. Pulmo-
nary-capillary blood volume was then calculated from the DLCO
measured by subtracting the resistance to diffusion associated
with alveolar-capillary barrier (DMCO) and correcting for
differences in the rate of uptake and binding to hemoglobin (1/
θ) due to differences in each subject's hemoglobin (Hb)
concentrations (14.6 g/dl being used as the normal hemoglobin
concentration) and the alveolar partial pressure of oxygen
(PAO2) using the following formula:
1
θCO
= ð0:73 + 0:0058 × PAO2Þ × 14:6Hb
2.3. Calculation of mean transit time
To calculate mean transit time (MTT) the following equation
was used:
MTT =
VCðml=minÞ= 1000ðml=lÞ
Qðl=minÞ ∗60 s=min
97
98
99
100
)
**
†
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At rest and during exercise amaximal expiratory flow volume
(MEFV) maneuver was completed following the rebreathe
maneuver to assess FVC, FEV1, FEF50, and FEF25–75 [40].
2.5. Assessment of hemoglobin
Hemoglobin was measured by a cyanide-free hemoglobin
method on an ADVIA 2120 Hematology system, at the
University of Arizona Medical Center Pathology Laboratory.
Hemoglobin concentration measured for each subject from the
blood sample taken upon arrival was utilized for the calculation
of VC as described previously.
2.6. Statistical analysis
All statistical analyses were performed using the SPSS
statistical software (v.17, SPSS Inc., Chicago, IL). Independent
samples t-tests were performed to examine the differences at
rest and at peak exercise between healthy and CF subjects. Prior
to analysis normality was ensured using Levene's test.
Confidence intervals were calculated for the mean difference
ðX healthy−X CFÞ: An interval not including the null hypothesis of
zero difference would corroborate with the determination of a
significant hypothesis testing result. We explored the relation-
ship between DLNO, DLCO, DM, FEV1 and FEV1/FVC with
SaO2 at rest and peak exercise for healthy and CF subjects using
Pearson's correlation. Regression analysis was conducted to
determine the ability of DLNO, FEV1 or FEV1/FVC to predict
SaO2 at peak exercise in CF subjects. An alpha level of 0.05 was
used to determine statistical significance. All data are presented
as mean±SD.
3. Results
Healthy, non-smoking and clinically stable CF subjects were
matched for gender, age, height and weight. As expected, the
CF subjects displayed lower pulmonary function values as well
as a reduced maximal oxygen capacity (VO2PEAK) compared to
their healthy counterparts (pb0.01, Tables 1 and 2).
At rest, there were no observed differences between healthy
and CF participants in VO2 or VC. However, patients with CFTable 2
Pulmonary function test parameters in cystic fibrosis and healthy subjects.
Healthy CF CI 95%
FVC (L) 4.6±1.3 3.4±0.9 ** (0.4, 2.0)
FVC (% predicted) 100±18 81±20 * (6.1, 32.9)
FEV1 (L/s) 3.8±0.8 3.8±0.9 † (0.7, 1.9)
FEV1(% predicted) 97±15 68±25 † (14.4, 43.4)
FEV1/FVC (%) 83±0.1 70±0.1 ** (0.1, 0.2)
FEF25–75 (L/s) 3.8±0.9 1.9±1.1 † (1.2, 2.6)
FEF25–75 (% predicted) 92±22 49±31 † (24.1, 61.5)
CF = cystic fibrosis; FVC = forced vital capacity; FEV1 = forced expiratory
volume after one second of FVC; FEF25−75 = forced expiratory flow at 25−75%
of FVC. Values are mean±SD and CI 95% is for the mean difference. *pb0.05,
**pb0.01, †pb0.001.demonstrated lower SaO2, DLNO, DLCO, and DM (pb0.01,
Figs. 1 and 2). Additionally, CF subjects demonstrated an
elevated dead space volume (VD) and lower alveolar volume
(VA) and Q (pb0.05, Table 3) There was a positive relationship
between resting SaO2 with resting DLNO, DLCO, DM and
FEV1 for CF subjects, but no relationship existed within healthy
subjects (Table 4).
At peak exercise, CF subjects demonstrated a significantly
lower workload, workload as a percentage of predicted
(WMAX), VT, VE, VA, Q, and cardiac index (CI) (pb0.01,
Table 3). Additionally, the percent change in VT and VE was
significantly different between groups (pb0.001, Table 3). The
CF group demonstrated increases in gas diffusion with exercise.
However, the degree of change from rest in DLCO and DLNO
were lower in the CF subjects (%ΔDLCO: p=0.02; %ΔDLNO:
p=0.06, Table 3). As such, DLNO, DLCO, DM and SaO2
remained lower at peak exercise in the CF patients (DLNO,
DLCO, DM: pb0.0001 SaO2: pb0.01). Although the change in
SaO2 from rest was not different between groups, we observed
significant desaturation in four of the CF subjects during testing.
Peak SaO2 was positively correlated with resting DLNO, FEV1
and FEV1/FVC, and peak DLNO, DLCO and DM in the patients
with CF (Table 4 and Fig. 3). With changes in exercise intensity
there was no change in the ratio of DLNO/DLCO in healthy or
CF subjects, nor was the ratio different between conditions
(Table 5).
At peak exercise, there was a negative relationship between
DLCO and FEV1 REST with SaO2 within healthy subjects
(DLCO: r=–0.53, p=0.04; FEV1 REST: r=–0.53, p=0.04).
Cardiac output was positively correlated with SaO2 and DLCO
(SaO2: r=0.78, p=0.00; DLCO: r=0.78, p=0.000) (Fig. 4).
Analysis of factors predicting SaO2 in CF patients at peak
exercise, demonstrated that resting DLNO explained 44% of the
variability in CF subjects and FEV1 or FEV1/FVC indepen-
dently could account for 50% and 27% of the variability,92
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Fig. 1. Peripheral oxygen saturation (SaO2) at rest and peak exercise in cystic
fibrosis and healthy subjects. The white bars represent subjects with cystic
fibrosis and the black bars represent healthy subjects. The first set of bars present
the comparison between groups at rest and the second set of bars show the
comparison at peak exercise. The error bars represent the standard error of the
mean. **=pb0.01, †=pb0.001.
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Fig. 2. Diffusion capacity of the lungs for nitric oxide (DLNO) and carbon dioxide (DLCO) and its components at rest and peak exercise in cystic fibrosis and healthy
subjects. 1st panel: DLNO. 2nd panel: DLCO. 3rd panel: alveolar-capillary membrane conductance (DM). 4th panel: pulmonary-capillary blood volume (VC). The
white bars represent subjects with CF and the black bars represent healthy subjects. The first set of bars present the comparison between groups at rest and the second
set of bars show the comparison at peak exercise. The error bars represent the standard error of the mean. *=pb0.05, **=pb0.01. †=pb0.001.
Table 3
Resting and peak workload and pulmonary parameters in cystic fibrosis and healthy subjects.
Rest Peak exercise
Healthy CF CI 95% Healthy CF CI 95%
Workload (W) 0 0 – 187±68 97±34 † (52.8, 128.4)
WMAX (%) 0 0 – 106±37 52±16 † (33.1, 73.9)
VO2 (mL/kg/min) 6±1 6±2 (−1.3, 1.0) 40±10 24±10 † (8.6, 22.8)
RR (breaths/min) 19±5 22±6 (−6.8, 1.3) 45±9 42±9 (−3.1, 9.8)
VT BTPS (ml) 746±240 783±324 (−237.7, 165.1) 2257±689 1493±449 † (348.1, 1180.0)
Δ in VT BTPS (%) – – – 225±106 92±82 † (66.5, 198.6)
VE BTPS (L/min) 14±4 16±6 (−6.0, 1.2) 100±31 59±12 † (24.3, 57.6)
Δ in VE BTPS (%) – – – 653±230 300±146 † (216.2, 492.2)
VA (ml) 291±67 207±59 † (393.9, 1277.8) 2952±743 2122±605 † (351.1, 1310.5)
VD(ml) 322±90 464±195 ** (−248.3, −36.4) 518±204 611±281 (24.2, 0.9)
Q (L/min) 5.6±2.0 4.4±1.5 * (0.1, 2.5) 15.7±6.0 11.1±3.9 * (1.1, 8.2)
CI (L/min/m2) 3.2±1.0 2.6±0.7 (−0.0, 1.3) 9.0±3.3 6.7±2.3 * (0.3, 4.3)
MTT (s) 0.65±0.25 0.67±0.30 (−0.2, 0.2) 0.35±0.10 0.41±0.16 (−0.1, 0.0)
Δ in DLNO (%) – – – 45±18 29±28 (−0.5, 33.4)
Δ in DLCO (%) – – – 47±15 32±21 * (2.4, 28.1)
Δ in SaO2 (%) – – – −1.4±2.0 −2.9±5.0 (−1.2, 4.2)
CF = cystic fibrosis; WMAX = peak workload as a percentage of predicted max; RR = respiratory rate; VT = tidal volume; VE = minute ventilation; VA = alveolar
volume; VD = dead space volume; Q = cardiac output; CI = cardiac index; MTT = mean transit time; Δ in DLNO (%) = percentage change from rest in DLNO; Δ in
DLCO (%) = percentage change from rest in DLCO;Δ in SaO2 (%) = percentage change from rest in peripheral oxygen saturation. Values are mean±SD and CI 95%
is for the mean difference. * pb0.05, **pb0.01, † pb0.001.
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Table 4
Relationship between pulmonary function, diffusion capacity parameters and
peripheral oxygen saturation at rest and at peak exercise in cystic fibrosis
subjects.
SaO2 rest SaO2 peak exercise
r p-value r p-value
DLNOREST 0.70 0.002 0.67 0.005
DLNOPEAK – – 0.65 0.006
DLCO 0.64 0.008 0.63 0.008
DM 0.70 0.03 0.68 0.004
FEV1 REST 0.54 0.03 0.71 0.002
FEV1/FVCREST 0.25 0.36 0.52 0.04
Table 5
Ratios of DLNO/DLCO with increasing exercise intensity in cystic fibrosis and
healthy subjects.
Exercise intensity (% Maximum Workload)
Rest 50% 100%
DLNO/DLCO healthy 3.28±0.30 3.04±0.29 3.22±0.32
DLNO/DLCO CF 3.21±0.33 3.02±0.40 3.09±0.19
50 C.M. Wheatley et al. / Journal of Cystic Fibrosis 10 (2011) 45–53respectively (Table 6). When both FEV1/FVC and DLNO were
included in the multiple regression model 56% of the variability
in SaO2 at peak exercise in CF patients was explained (Table 6).
DLNOaccounted for the largest portion of the explained variation
and FEV1/FVC accounted for the smaller portion of the variation.
There was no evidence of multicolinearity. The equation of the
model was SaO2=72.79+0.16(DLNOREST) +16.00(FEV1/
FVC).
4. Discussion
The diffusion capacity of the lungs for nitric oxide and the
components of DLCO have not been reported in individuals
with CF during exercise before, highlighting the originality of
this study which adds to previous work which has been unable
to determine whether there is a reduction in DM, VC or both in
this patient population. Our results demonstrate that DLNO,
DLCO, DM are lower when compared to healthy subjects at rest
and peak exercise. There is a limited exercise-induced increase
in these gas diffusion parameters in CF exercise. There is no
difference in VC in patients with CF compared to healthyFig. 3. Relationship between peripheral oxygen saturation (SaO2) at peak
exercise and resting diffusion of the lungs for nitric oxide (DLNO), diffusion of
the lungs for carbon monoxide (DLCO) and alveolar-capillary membrane
conductance (DM). The X-axis represents DLNO: r=0.65, p=0.006 (black),
DLCO: r=0.63, p=0.008 (grey) or DM: r=0.68, p=0.004 (white) and the Y-axis
represents SaO2.individuals. Our assessment of a decrease in DLCO adds to
previous work in CF, where DLCO values have been reported
as elevated, decreased or normal [30,41–44]. Both DLCO and
DLNO are measures of the capacity of the lungs for gas transfer,
but since nitric oxide has a faster rate of reaction with
hemoglobin than carbon monoxide, it has been proposed as a
direct measure of membrane conductance since it remains
unaffected by fluctuations in VC [26,28]. Alveolar-capillary
membrane conductance represents the ability of gases to pass
from the alveolar airspace to the blood, and it is dependent on
the physiochemical characteristics of the membrane. Pulmonary
capillary blood volume represents the total volume of blood in
contact with the alveoli, where increases in VC result in an
increase in diffusion capacity.
Previous research has demonstrated that DLNO is mainly
dependent on VA and workload [45]. When we corrected
DLNO for VA and compared healthy and CF subjects at the
same relative workload intensity rest and peak exercise, we
found that there was no difference between groups (rest: 26.2±
4.9 vs. 27.8±7.7 ml/min/mmHg/ml; peak: 37.2±7.3 vs. 33.8±
6.87 ml/min/mmHg/ml). These results suggest that the primary
factor limiting membrane conductance in CF is limitations in
alveolar ventilation. Previous work has demonstrated that theFig. 4. Relationship between peripheral oxygen saturation (SaO2), diffusion of
the lungs for carbon monoxide (DLCO), and cardiac output (Q) at peak exercise
in healthy subjects. The Y-axis represents SaO2, the X-axis represents DLCO
and the Z-axis represents Q. SaO2 vs. DLCO: r=−0.53, p=0.04; SaO2 vs.
Q: r=0.78, p=0.000; DLCO vs. Q: r=0.78, p=0.000.
Table 6
Linear regression analysis.
Predictors F(1,14) R R
2 p-value
DLNOREST (ml/min/mmHg) 11.15 0.67 0.44 0.002
FEV1REST (ml) 13.9 0.71 0.50 0.002
FEV1/FVC REST 5.19 0.52 0.27 0.04
DLNOREST, FEV1/FVC REST 8.31 0.75 0.56 0.005
Coefficient
B β p-value Tolerance
SaO2 intercept (%) 72.79 – 0.00 –
DLNOREST (ml/min/mmHg) 0.16 0.56 0.01 0.92
FEV1/FVC REST 16.00 0.36 0.08 0.92
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conditions resulted in an increase in DLNO and DLCO.
Conversely, hyperoxic conditions lead to reductions in DLNO
and DLCO determined by rebreathing in canines [46]. As there
is the potential for the lungs to become hypoxic in CF patients
due to hyperinflation and gas trapping which can reduce overall
alveolar oxygen partial pressure (PAO2), it is important to note
that PAO2 was not different between healthy and CF subjects at
rest or peak exercise (rest: 154.2±9.4 vs. 157.3±8.3 mmHg;
peak: 138.0±12.3 vs. 139.3±11.3 mmHg, healthy vs. CF
respectively). As well in the calculation of DM and VC,
corrections are made for differences in PAO2. Inhomogenous
ventilation of airways which can be present in patients with CF,
can also affect measurements of diffusion capacity. However, it
has been previously demonstrated that the heterogeneity of
alveolar gas composition is diminished when measurements of
diffusion capacity of the lungs are conducted using the
rebreathe rather than the breathe hold method, because of the
opportunity for better mixing. As such, the effects of functional
inhomogeneities are reduced, although not completely sup-
pressed because ventilation cannot be sufficiently increased
[47]. Finally, in regards to the potential influence of
hyperinflation on the assessment of DLCO, work by Baldi et
al. explored the influence of hyperinflation (using pulmonary
function testing) and CT scanning for degree of emphesyma on
DLCO. The authors found that there was a negative relationship
between hyperinflation and DLCO. With respect to our work,
this would mean our measurement of DLCO in the CF patients
may be lower than actual reality and so it is possible we
overestimate the difference in DLCO between the CF patients
and the healthy subjects. However, the presence of a true
diffusion limitation is likely, given the nature of CF, and is in
agreement with previous studies.
The DLNO/DLCO ratio of 3.1 measured in healthy subjects
for this study was shown to be independent of exercise intensity
as has been demonstrated previously, but our ratio was lower
than the values that have been reported by others which were
4.3 and 4.0 [23,48,49]. Adding to this previous work, our study
is now the first to demonstrate that the DLNO/DLCO ratio is
also unchanged with increasing exercise intensity in individuals
with CF and that this ratio was also not different when
compared to healthy subjects.Although our findings of a correlation between DLCO and
SaO2 at peak exercise is in agreement with some, it conflicts
with work by Chemery et al. which may be a consequence of
this previous work not partitioning the components of DLCO
[16,29–31]. Since we found VC to be similar between CF and
healthy subjects at rest and peak exercise and no correlation
with SaO2, but a significant reduction in DLNO, DLCO and DM
in the CF patients and significant positive relationships between
these variables and SaO2, our findings demonstrate that the
primary limitation to the diffusion capacity in individuals with
CF is membrane conductance. Although we have shown
limitation in the percent change in DLNO and DLCO in CF
subjects, individuals with CF demonstrated an ability to
increase DLNO and DLCO with exercise for a limited duration.
Previous research focused on identifying factors related to
desaturation during exercise or formal hypoxic challenge in CF
subjects has found resting SaO2, FEV1 and other pulmonary
function measures, BMI, radiological and clinical score to be
associated with peak SaO2, but as predictors these factors have
not always demonstrated reliability [10,15–18,50]. Studies
have shown that CF patients with single breath DLCON80% or
FEV1N70% predicted did not desaturate with exercise
[2,10,16–18]. An important finding from our work is that
DLNO at rest was also strong predictor of desaturation during
exercise. When resting DLNO and FEV1/FVC were both
included in our model for prediction of SaO2 at peak exercise,
56% of the variability in oxygen saturation was explained
demonstrating that both limitation in membrane conductance
and airway obstruction contribute to exercise-induced desatura-
tion in CF. By utilizing data about both the diffusion capacity
and the extent of airflow for a CF patient, there was a slight
increase from 50 to 56% in the explained variance in SaO2 with
this model compared to that which was explained by FEV1
alone. However, due to the small sample size this prediction
model should be used to guide future work where there is
recruitment of a larger sample to further investigate if FEV1 is a
superior predictor or provide support for our findings that
diffusion capacity data can assist in predicting desaturation.
Interestingly, our findings involving healthy subjects
demonstrate a negative relationship between DLCO and
SaO2, but a positive correlation between DLCO and Q. This
suggests that the high Q contributes directly to the inverse
relationship of DLCO and SaO2, where a high flow rate causes a
decrease in mean transit time of blood through the lungs, which
averaged 0.35 s at peak exercise (Table 3), providing
inadequate time for complete hemoglobin saturation.
4.1. Limitations
In the present study SaO2 was assessed by pulse oximetry
which is not as sensitive as direct arterial blood draws to
determine SaO2. However, a meta-analysis demonstrated a
strong relationship between SaO2 measured using a pulse
oximeter and direct blood gas analysis [51]. All subjects were of
Caucasian or Hispanic ethnicity so the accuracy of pulse
oximetry would not have been reduced due to darker skin color
[52]. Orenstein et al. in a study comparing pulse oximeters
52 C.M. Wheatley et al. / Journal of Cystic Fibrosis 10 (2011) 45–53demonstrated that the Nellcor 100, an older model than what
was used in this study, had the lowest overall bias, but during
episodes of hypoxemia the device tended to overestimate true
desaturation [53]. Additionally, Yamaya et al. have demon-
strated that finger sensors tended to lose precision and accuracy
when saturation neared or dropped below 90% [54]. As such,
the change in SaO2 measured in this study may under
represented the true desaturation experienced in four of our
subjects who's SaO2 neared or dropped below 90%. Future
studies with arterial O2 measurement and recruitment of a larger
subject population are needed to confirm these findings. Also
since our CF patient population demonstrated a range in disease
severity and our sample size was not large enough to partition
the patient population into mild and moderate, we are unable to
provide any conclusions on whether the differences we noted
are present early in the disease process. Future work with
recruitment of a larger CF patient population with sufficient
numbers to allow for stratification into mild, moderate and
severe lung disease are needed to determine when impairments
in diffusion capacity of the lungs presents in CF.
5. Conclusion
Decrements in DLCO during exercise have been previously
documented, but assessment of membrane conductance by
measurement of DLNO or DM and VC has not been reported
during exercise in CF. Our study adds to previous work by
providing three important findings. First, our results demonstrate
that CF patients have a reducedDLNO, DLCO and DM at rest and
a limited exercise-induced increase. During exercise CF subjects
demonstrate an increase in membrane conductance, but a drop in
SaO2, suggesting an inadequate increase in membrane conduc-
tance to compensate for increased Q and prevent desaturation.
Second, these results highlight the importance of assessingDLNO
and the components ofDLCO, indicating impairment inDM rather
than a limitation in VC contribute to desaturation during exercise
in individuals with CF. Additionally, when comparing DLNO
corrected for VA there was no difference between groups,
suggesting that the limitations in membrane conductance in CF
are primarily the consequence of reductions in alveolar ventila-
tion. Finally, in the attempt to predict CF patientswho are at risk of
desaturation the assessment ofDLNO at rest appears to be a strong
predictor. This novel finding is important because Dressel et al.
demonstrated that DLNO was better correlated with CF-specific
CT score than DLCO, concluding that DLNO was a suitable
measure to quantify destruction and structural alterations in theCF
lung [28]. Collectively, these findings suggest that the assessment
of DLNO or DLCO with partitioning of DM and VC can provide
important information about the transfer of gas from the lungs to
the blood stream to compliment the data regarding the exchange of
gas between the lungs and the environment that is normally
obtained clinically through resting pulmonary function testing.
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